Nycomed, Neurochem gang up on Alzheimer’s

Nycomed and Neurochem have struck an alliance aimed at developing novel technologies for the diagnosis of Alzheimer’s disease. Using Neurochem’s proprietary molecules as a basis, the two companies will work on the design and selection of a product to detect the presence of amyloid plaques that accumulate in the brains of Alzheimer’s patients.